Protocol Ledger

NCT05438498 · Phase III · TERMINATED

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

Interventional Phase III clinical trial protocol NCT05438498 sponsored by MediMergent in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-03 Enrollment: 550 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05438498
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)550 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05438498
Protocol FieldVerified Registry Value
NCT IdentifierNCT05438498
Consolidated Lead SponsorMediMergent
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment550 participants (ACTUAL)
Registered Start Date2022-06-03
WhyStopped ClassificationUnspecified

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI